COMP <GO>
NCNA vs DRMA // EV/EBITDA & P/E VALUATION
NuCana plc (NASDAQ) VS. Dermata Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NCNA 2
— DRMA 0
■ METRIC PARITY
LAST: $1.04 (-3.26%) • MKT CAP: $4.3M
valuation
—
LAST: $0.84 (-3.84%) • MKT CAP: $4.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NCNA VS. DRMA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NCNA | DRMA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 1/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.3 | 39.9 | +0.47 | NCNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.3M | $4.2M | $160.6K | NCNA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NCNA REV | DRMA REV | NCNA GROSS % | DRMA GROSS % | NCNA FCF | DRMA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$7.8M |
| FY 2024 | — | $0 | — | — | — | -$11.2M |
| FY 2023 | — | $0 | — | — | — | -$6.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NCNA // BETA —
DRMA // BETA —